Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model

Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis

“…This has been previously shown in a metaanalysis, which identified similar survival rates between patients who received SBRT and those who received surgery only after adjusting for age and %Op [102]. This finding has been corroborated in a pooled analysis of 2 RCTs, while unadjusted data still favored surgery [12,101,105]. The current study is limited by considerable selection bias due to that most studies included in the analysis were single- institutional, single-arm, observational studies from various continents of the world with great heterogeneity, including variation in quality.…”

“…This survival benefit did not reach its statistical significance after adding %Op into the final multivariate analysis ( p = 0.11). %Op appeared to be the strongest factor affecting patient survival among all study characteristics, implying significant influence of patients' functional performance and comorbidities on survival following high-dose irradiation in patients with ES NSCLC [100]; and the importance of identifying and adjusting for valid prognostic and predictive factors for survival and treatment-related toxicities following high dose irradiation when comparing the efficacy of different treatments [101–103]. These include patient, tumor, dosimetric, imaging characteristics, and biomarkers.…”

Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms

“…In turn, such predictions can play an important role in patient risk stratification and treatment decision making. Our models improve upon previously published nomograms 5,6 in study population size, range of predictors, and evaluation of recurrence endpoints, together resulting in enhanced predictive ability and potential applicability toward clinical patient selection.…”

“…At present, there have been 2 nomograms developed for ES-NSCLC treated with SABR. The Amsterdam prognostic model, reported by Louie et al, 5 was the first nomogram developed for such patients and demonstrated promise in survival predictions; however, OS was the only reported endpoint in this study. In contrast, the second model, by Ye et al, 6 was developed from a small sample database of 182 patients, lending to concerns regarding applicability and detection of important prognostic factors.…”

Defining the role of radiofrequency ablation and stereotactic ablative radiotherapy in patients with high‐risk, early‐stage non‐small cell lung cancer

“…1 The Radiation Therapy Oncology Group (RTOG) 0236 trial was an important multicenter study that established the role of SBRT in medically inoperable patients. 2 The sample size for the RTOG 0236 trial was 55 patients, which was similar to the 54 patients in the American College of Surgeons Oncology Group Z4033 (Alliance) cooperative group study (hereafter referred to as the Z4033 study). The 3-year survival rate in the RTOG 0236 trial was 55.8% and a review of their published survival curve demonstrated a 2-year survival rate of 72%, which is similar to the 2-year survival rate after RFA noted in the Z4033 study.…”